Subjective preference for lamotrigine or topiramate in healthy volunteers: Relationship to cognitive and behavioral functioning

Mary Ann Werz, Mike R. Schoenberg, Kimford J. Meador, David W. Loring, Patty G. Ray, Rina Kaul-Gupta, Paula Ogrocki

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective. Outcomes research emphasizes patient self-assessment and preferences in optimizing treatment. We previously showed that lamotrigine produces significantly less cognitive and behavioral impairment compared with topiramate. In the current study we extend these observations to subject self-report of preference for lamotrigine or topiramate independent of potentially confounding effects of seizures or seizure control. Additionally, drug preference was related to effects of lamotrigine and topiramate on objective neuropsychological tests as well as self-perception on behavioral instruments. Methods: Thirtyseven healthy volunteers completed a double-blind, randomized crossover design incorporating tow 12-week treatment periods of lamotrigine and topiramate each titrated to a dose of 300 mg/day. Evaluation of 23 objective neuropsychological and 15 subjective behavioral measures occurred at four times: pretreatment baseline, first treatment, second treatment, and posttreatment baseline. Preference for lamotrigine or topiramate was assessed, while blinding was maintained, at the final study visit when each subject was asked which drug he or she would prefer to take. Results: A large majority (70%) preferred lamotrigine, 16% stated preference for topiramate, and 14% had no preference (drugs equivalent). Consistennt with preference, those preferring lamotrigine performed better on 19 of 23 objective and 13 of 15 subjective behavioral measurement while on lamotrigine. Inconsistent with preference, subjects preferring topiramate performed better on 19 of 23 objective and 9 of 15 subjective behavioral measures while on lamotrigine. Topiramate preference also did not correlate with IQ, serum concentration, body mass index, age, or gender. Topiramate preference did relateto responses on the Profile of Mood States. Conclusion: Lamotrigine was preferred by the majority of subjects, congruent with objective neuropsychological and subjective behavioral measures. In contrast, for those stating a preference for topiramate the results on objective neuropsychological measures were impaired while fewer complaints were noted on the Profile of Mood States. This suggests that preference for topiramate may be determined by an effect on mood.

Original languageEnglish (US)
Pages (from-to)181-191
Number of pages11
JournalEpilepsy and Behavior
Volume8
Issue number1
DOIs
StatePublished - Feb 1 2006

Fingerprint

Healthy Volunteers
Seizures
topiramate
lamotrigine
Pharmaceutical Preparations
Neuropsychological Tests
Therapeutics
Self Concept
Cross-Over Studies
Self Report
Body Mass Index
Outcome Assessment (Health Care)
Serum

Keywords

  • Cognition
  • Drug preference
  • Epilepsy health outcome
  • Lamotrigine
  • Mood
  • Topiramate

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Werz, M. A., Schoenberg, M. R., Meador, K. J., Loring, D. W., Ray, P. G., Kaul-Gupta, R., & Ogrocki, P. (2006). Subjective preference for lamotrigine or topiramate in healthy volunteers: Relationship to cognitive and behavioral functioning. Epilepsy and Behavior, 8(1), 181-191. https://doi.org/10.1016/j.yebeh.2005.09.003

Subjective preference for lamotrigine or topiramate in healthy volunteers : Relationship to cognitive and behavioral functioning. / Werz, Mary Ann; Schoenberg, Mike R.; Meador, Kimford J.; Loring, David W.; Ray, Patty G.; Kaul-Gupta, Rina; Ogrocki, Paula.

In: Epilepsy and Behavior, Vol. 8, No. 1, 01.02.2006, p. 181-191.

Research output: Contribution to journalArticle

Werz, Mary Ann ; Schoenberg, Mike R. ; Meador, Kimford J. ; Loring, David W. ; Ray, Patty G. ; Kaul-Gupta, Rina ; Ogrocki, Paula. / Subjective preference for lamotrigine or topiramate in healthy volunteers : Relationship to cognitive and behavioral functioning. In: Epilepsy and Behavior. 2006 ; Vol. 8, No. 1. pp. 181-191.
@article{75275961d71f4bf990b45a5170251cd5,
title = "Subjective preference for lamotrigine or topiramate in healthy volunteers: Relationship to cognitive and behavioral functioning",
abstract = "Objective. Outcomes research emphasizes patient self-assessment and preferences in optimizing treatment. We previously showed that lamotrigine produces significantly less cognitive and behavioral impairment compared with topiramate. In the current study we extend these observations to subject self-report of preference for lamotrigine or topiramate independent of potentially confounding effects of seizures or seizure control. Additionally, drug preference was related to effects of lamotrigine and topiramate on objective neuropsychological tests as well as self-perception on behavioral instruments. Methods: Thirtyseven healthy volunteers completed a double-blind, randomized crossover design incorporating tow 12-week treatment periods of lamotrigine and topiramate each titrated to a dose of 300 mg/day. Evaluation of 23 objective neuropsychological and 15 subjective behavioral measures occurred at four times: pretreatment baseline, first treatment, second treatment, and posttreatment baseline. Preference for lamotrigine or topiramate was assessed, while blinding was maintained, at the final study visit when each subject was asked which drug he or she would prefer to take. Results: A large majority (70{\%}) preferred lamotrigine, 16{\%} stated preference for topiramate, and 14{\%} had no preference (drugs equivalent). Consistennt with preference, those preferring lamotrigine performed better on 19 of 23 objective and 13 of 15 subjective behavioral measurement while on lamotrigine. Inconsistent with preference, subjects preferring topiramate performed better on 19 of 23 objective and 9 of 15 subjective behavioral measures while on lamotrigine. Topiramate preference also did not correlate with IQ, serum concentration, body mass index, age, or gender. Topiramate preference did relateto responses on the Profile of Mood States. Conclusion: Lamotrigine was preferred by the majority of subjects, congruent with objective neuropsychological and subjective behavioral measures. In contrast, for those stating a preference for topiramate the results on objective neuropsychological measures were impaired while fewer complaints were noted on the Profile of Mood States. This suggests that preference for topiramate may be determined by an effect on mood.",
keywords = "Cognition, Drug preference, Epilepsy health outcome, Lamotrigine, Mood, Topiramate",
author = "Werz, {Mary Ann} and Schoenberg, {Mike R.} and Meador, {Kimford J.} and Loring, {David W.} and Ray, {Patty G.} and Rina Kaul-Gupta and Paula Ogrocki",
year = "2006",
month = "2",
day = "1",
doi = "10.1016/j.yebeh.2005.09.003",
language = "English (US)",
volume = "8",
pages = "181--191",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Subjective preference for lamotrigine or topiramate in healthy volunteers

T2 - Relationship to cognitive and behavioral functioning

AU - Werz, Mary Ann

AU - Schoenberg, Mike R.

AU - Meador, Kimford J.

AU - Loring, David W.

AU - Ray, Patty G.

AU - Kaul-Gupta, Rina

AU - Ogrocki, Paula

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Objective. Outcomes research emphasizes patient self-assessment and preferences in optimizing treatment. We previously showed that lamotrigine produces significantly less cognitive and behavioral impairment compared with topiramate. In the current study we extend these observations to subject self-report of preference for lamotrigine or topiramate independent of potentially confounding effects of seizures or seizure control. Additionally, drug preference was related to effects of lamotrigine and topiramate on objective neuropsychological tests as well as self-perception on behavioral instruments. Methods: Thirtyseven healthy volunteers completed a double-blind, randomized crossover design incorporating tow 12-week treatment periods of lamotrigine and topiramate each titrated to a dose of 300 mg/day. Evaluation of 23 objective neuropsychological and 15 subjective behavioral measures occurred at four times: pretreatment baseline, first treatment, second treatment, and posttreatment baseline. Preference for lamotrigine or topiramate was assessed, while blinding was maintained, at the final study visit when each subject was asked which drug he or she would prefer to take. Results: A large majority (70%) preferred lamotrigine, 16% stated preference for topiramate, and 14% had no preference (drugs equivalent). Consistennt with preference, those preferring lamotrigine performed better on 19 of 23 objective and 13 of 15 subjective behavioral measurement while on lamotrigine. Inconsistent with preference, subjects preferring topiramate performed better on 19 of 23 objective and 9 of 15 subjective behavioral measures while on lamotrigine. Topiramate preference also did not correlate with IQ, serum concentration, body mass index, age, or gender. Topiramate preference did relateto responses on the Profile of Mood States. Conclusion: Lamotrigine was preferred by the majority of subjects, congruent with objective neuropsychological and subjective behavioral measures. In contrast, for those stating a preference for topiramate the results on objective neuropsychological measures were impaired while fewer complaints were noted on the Profile of Mood States. This suggests that preference for topiramate may be determined by an effect on mood.

AB - Objective. Outcomes research emphasizes patient self-assessment and preferences in optimizing treatment. We previously showed that lamotrigine produces significantly less cognitive and behavioral impairment compared with topiramate. In the current study we extend these observations to subject self-report of preference for lamotrigine or topiramate independent of potentially confounding effects of seizures or seizure control. Additionally, drug preference was related to effects of lamotrigine and topiramate on objective neuropsychological tests as well as self-perception on behavioral instruments. Methods: Thirtyseven healthy volunteers completed a double-blind, randomized crossover design incorporating tow 12-week treatment periods of lamotrigine and topiramate each titrated to a dose of 300 mg/day. Evaluation of 23 objective neuropsychological and 15 subjective behavioral measures occurred at four times: pretreatment baseline, first treatment, second treatment, and posttreatment baseline. Preference for lamotrigine or topiramate was assessed, while blinding was maintained, at the final study visit when each subject was asked which drug he or she would prefer to take. Results: A large majority (70%) preferred lamotrigine, 16% stated preference for topiramate, and 14% had no preference (drugs equivalent). Consistennt with preference, those preferring lamotrigine performed better on 19 of 23 objective and 13 of 15 subjective behavioral measurement while on lamotrigine. Inconsistent with preference, subjects preferring topiramate performed better on 19 of 23 objective and 9 of 15 subjective behavioral measures while on lamotrigine. Topiramate preference also did not correlate with IQ, serum concentration, body mass index, age, or gender. Topiramate preference did relateto responses on the Profile of Mood States. Conclusion: Lamotrigine was preferred by the majority of subjects, congruent with objective neuropsychological and subjective behavioral measures. In contrast, for those stating a preference for topiramate the results on objective neuropsychological measures were impaired while fewer complaints were noted on the Profile of Mood States. This suggests that preference for topiramate may be determined by an effect on mood.

KW - Cognition

KW - Drug preference

KW - Epilepsy health outcome

KW - Lamotrigine

KW - Mood

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=30844450089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30844450089&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2005.09.003

DO - 10.1016/j.yebeh.2005.09.003

M3 - Article

C2 - 16377253

AN - SCOPUS:30844450089

VL - 8

SP - 181

EP - 191

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 1

ER -